TABLE 3.
Susceptibility of Enterobacteriaceae to selected antimicrobial agents according to patient age and isolate specimen source in 2001
| Patient age and specimen source | % of isolates susceptible to antimicrobial agent (no. of isolates tested)a
|
||||||
|---|---|---|---|---|---|---|---|
| Ceftazidime | Imipenem | Piperacillin-tazobactam | Gentamicin | SXT | Ciprofloxacin | Levofloxacin | |
| Age | |||||||
| <18 yr | 84.0 (6,812) | 100 (5,705) | 85.9 (4,840) | 92.2 (9,227) | 83.1 (9,194) | 98.3 (7,254) | 98.5 (6,595) |
| 18-65 yr | 89.5 (23,187) | 100 (20,851) | 89.5 (19,997) | 93.6 (36,292) | 83.8 (35,746) | 89.5 (26,135) | 90.3 (25,872) |
| >65 yr | 90.4 (19,703) | 100 (19,592) | 90.7 (18,451) | 93.3 (34,182) | 84.3 (34,034) | 87.0 (24,882) | 86.3 (26,259) |
| Specimen source | |||||||
| Blood | 88.6 (5,002) | 100 (4,921) | 89.3 (4,554) | 91.2 (6,252) | 81.5 (6,068) | 88.8 (4,928) | 89.0 (4,383) |
| Respiratory | 83.5 (10,130) | 100 (9,150) | 84.2 (9,154) | 91.2 (12,481) | 88.8 (12,069) | 89.2 (8,934) | 88.9 (8,510) |
| Urine | 92.8 (27,526) | 100 (25,607) | 92.7 (22,179) | 92.7 (25,607) | 82.8 (51,441) | 89.7 (38,644) | 89.7 (40,171) |
a
Demographic and specimen source data were not available for all isolates.